80900 Federal Register / Vol. 89, No. 193 / Friday, October 4, 2024 / Notices 

Shoemaker, Chief, Banking and 

Regulatory Policy, 202–898–6962, 

kashoemaker@fdic.gov; Legal Division: 

Sheikha Kapoor, Assistant General 

Counsel, 202–898–3960, skapoor@

fdic.gov; Vivek Khare, Senior Counsel, 

202–898–6847; or Ryan McCarthy, 

Counsel, 202–898–7301, rymccarthy@

fdic.gov. 

SUPPLEMENTARY INFORMATION: On August 

6, 2024, the FDIC published in the 

Federal Register an RFI and comment 

soliciting comments on deposit data that 

is not currently reported in the FFIEC 

Call Report or other regulatory reports, 

including for uninsured deposits. The 

FDIC issued the RFI to seek information 

on the characteristics that affect the 

stability and franchise value of different 

types of deposits and whether more 

detailed or more frequent reporting on 

these characteristics or types of deposits 

could enhance offsite risk and liquidity 

monitoring, inform analysis of the 

benefits and costs associated with 

additional deposit insurance coverage 

for certain types of deposits, improve 

risk sensitivity in deposit insurance 

pricing, and provide analysts and the 

general public with accurate and 

transparent data. The RFI stated that the 

comment period would close on 

October 7, 2024. The FDIC has received 

requests to extend the comment period. 

An extension of the comment period 

will allow interested parties additional 

time to prepare information and 

comments. Therefore, the FDIC is 

extending the end of the comment 

period for the RFI from October 7, 2024, 

to December 6, 2024. 

Federal Deposit Insurance Corporation. 

Dated at Washington, DC, on October 1, 

2024. 

James P. Sheesley, 

Assistant Executive Secretary. 

[FR Doc. 2024–23010 Filed 10–3–24; 8:45 am] 

BILLING CODE 6714–01–P 

FEDERAL DEPOSIT INSURANCE 

CORPORATION 

Notice of Termination of Receiverships 

The Federal Deposit Insurance 

Corporation (FDIC or Receiver), as 

Receiver for each of the following 

insured depository institutions, was 

charged with the duty of winding up the 

affairs of the former institutions and 

liquidating all related assets. The 

Receiver has fulfilled its obligations and 

made all dividend distributions 

required by law. 

NOTICE OF TERMINATION OF RECEIVERSHIPS 

Fund Receivership name City State Termination date 

10221 ................................................................... Lincoln Park Savings Bank .................... Chicago .................. IL 10/01/2024 

10486 ................................................................... Community South Bank ......................... Parsons .................. TN 10/01/2024 

10524 ................................................................... Seaway Bank and Trust Company ........ Chicago .................. IL 10/01/2024 

The Receiver has further irrevocably 

authorized and appointed FDICCorporate as its attorney-in-fact to 

execute and file any and all documents 

that may be required to be executed by 

the Receiver which FDIC-Corporate, in 

its sole discretion, deems necessary, 

including but not limited to releases, 

discharges, satisfactions, endorsements, 

assignments, and deeds. Effective on the 

termination dates listed above, the 

Receiverships have been terminated, the 

Receiver has been discharged, and the 

Receiverships have ceased to exist as 

legal entities. 

(Authority: 12 U.S.C. 1819) 

Federal Deposit Insurance Corporation. 

Dated at Washington, DC, on October 1, 

2024. 

James P. Sheesley, 

Assistant Executive Secretary. 

[FR Doc. 2024–22964 Filed 10–3–24; 8:45 am] 

BILLING CODE 6714–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–24–1310] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Public Health 

Laboratory Testing for Emerging 

Antibiotic Resistance and Fungal 

Threats’’ to the Office of Management 

and Budget (OMB) for review and 

approval. CDC previously published a 

‘‘Proposed Data Collection Submitted 

for Public Comment and 

Recommendations’’ notice on June 17, 

2024 to obtain comments from the 

public and affected agencies. CDC did 

not receive comments related to the 

previous notice. This notice serves to 

allow an additional 30 days for public 

and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 193 / Friday, October 4, 2024 / Notices 80901 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Public Health Laboratory Testing for 

Emerging Antibiotic Resistance and 

Fungal Threats (0920–1310, Exp. 5/31/ 

2026)—Revision—National Center for 

Emerging and Zoonotic Infectious 

Diseases (NCEZID), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

Antimicrobial resistance has the 

potential to impact all Americans at 

every stage of life and the Centers for 

Disease Control and Prevention (CDC) is 

working to drive aggressive action and 

empower the nation to comprehensively 

respond to these threats. The National 

Action Plan Sub-Objective 2.1.1 

describes creation of ‘‘a regional public 

health laboratory network that uses 

standardized testing platforms to 

expand the availability of reference 

testing services’’, and facilitation of 

‘‘rapid data analysis and dissemination 

of information.’’ The CDC has created 

this public health laboratory network 

and named it the Antimicrobial 

Resistance Laboratory Network (AR Lab 

Network). The mission of the AR Lab 

Network is to offer validated highquality laboratory testing through 

funding support of state and regional 

labs so these labs can build the capacity 

and the capability to locally improve 

detection and laboratory diagnostics. 

Building strength nationally through 

public health laboratories thereby 

increases the capacity of state and local 

health departments for rapid detection 

and faster response to outbreaks and 

emerging antimicrobial resistance 

among bacterial and fungal pathogens 

(https://www.cdc.gov/antimicrobialresistance/media/pdfs/2019-ar-threatsreport-508.pdf). This state and local 

public health laboratory testing capacity 

is being implemented by the 

Department of Health and Human 

Services (HHS), Centers for Disease 

Control and Prevention (CDC) in 

response to the Executive Order 13676 

of September 18, 2014, the National 

Strategy of September 2014 and to 

implement the National Action Plan of 

October 2020 for Combating AntibioticResistant Bacteria. Data collected 

throughout this network is also 

authorized by Section 301 of the Public 

Health Service Act (42 U.S.C. 241). 

The CDC’s AR Lab Network supports 

nationwide lab capacity to rapidly 

detect antimicrobial resistance and 

inform local public health responses to 

prevent spread and protect people. It 

closes the gap between local laboratory 

capabilities and the data needed to 

combat antimicrobial resistance by 

providing comprehensive lab capacity 

and infrastructure for detecting 

antimicrobial-resistant pathogens 

(germs), advanced technology, like DNA 

sequencing, and rapid sharing of 

actionable data to drive infection 

control responses and help treat 

infections. This infrastructure allows 

the public health community to rapidly 

detect emerging antimicrobial-resistant 

threats in healthcare, food, and the 

community, mount a comprehensive 

local response, and better understand 

these deadly threats to quickly contain 

them. 

The AR Lab Network is a network of 

jurisdictional public health laboratories 

currently including those of all 50 

states, District of Columbia, Los Angeles 

County, Houston, New York City, 

Philadelphia, Guam, and Puerto Rico. 

Laboratories are financially supported 

through the Epidemiology and 

Laboratory Capacity for Prevention and 

Control of Emerging Infectious Diseases 

(ELC) Cooperative agreement (CDC– 

RFA–CK–24–0002) to perform testing, 

support workforce, and laboratory 

infrastructure. Laboratory capacity 

supported through the AR Lab Network 

fall into the following categories: (1) 

core testing, support for important 

antimicrobial resistant pathogens that 

are traditionally healthcare-associated, 

including carbapenem-resistant 

Enterobacteriaceae (CRE), carbapenemresistant Pseudomonas aeruginosa 

(CRPA), carbapenem-resistant 

Acinetobacter baumannii (CRAB), and 

Candida species, including C. auris; (2) 

jurisdictional testing capacity that 

supports Neisseria gonorrhoeae 

surveillance; (3) testing of colonization 

screening samples to support local 

public health response; and (4) 

enhanced testing capacity at the 

regional laboratories (currently seven). 

CDC is requesting a three-year 

approval for revisions made to OMB 

Control No. 0920–1310 for the Public 

Health Laboratory Testing for Emerging 

Antibiotic Resistance and Fungal 

Threats which supports the data 

collected through the Antimicrobial 

Resistance Laboratory Network (AR Lab 

Network). A Revision is being submitted 

to: (1) add new data elements to the data 

collection forms: (2) ensure that the 

burden of generating electronic 

messages for data transmission are 

accounted for; and (3) accommodate 

changes to the Performance Measures 

(PMs) used to monitor the performance 

of the AR Lab Network. For this 

Revision, the total estimated annual 

burden is 57,872 hours. There are no 

costs to respondents other than their 

time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of 

respondents Form name Number of respondents 

Average 

number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Public Health Laboratories .............. I.1—ROUTINE TESTING BY GENERAL IN JURISDICTION—Annual Evaluation and Performance 

Measurement Report.

57 1 10/60 

1.2—EXPANDED DRUG SUSCEPTIBILITY TESTING (ExAST) IN JURISDICTION—Annual Evaluation and Performance Measurement Report.7 1 10/60 

1.3—CANDIDA SPECIES IDENTIFICATION IN JURISDICTION—Annual Evaluation and Performance 

Measurement Report.

57 1 10/60 

1.4—HAIAR WHOLE GENOME SEQUENCING 

(WGS) OF GRAM–NEGATIVE AR THREATS IN 

JURISDICTION—Annual Evaluation and Performance Measurement Report.

Up to 57 1 10/60 


khammond on DSKJM1Z7X2PROD with NOTICES
80902 Federal Register / Vol. 89, No. 193 / Friday, October 4, 2024 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of 

respondents Form name Number of respondents 

Average 

number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

1.5—C. AURIS COLONIZATION SCREENING IN 

JURISDICTION—Annual Evaluation and Performance Measurement Report.

Up to 57 1 10/60 

1.6—CARBAPENEMASE–PRODUCING ORGANISM 

(CPO) SCREENING IN JURISDICTION—Annual 

Evaluation and Performance Measurement Report.

Up to 57 1 10/60 

1.7—AZOLE RESISTANCE IN CLINICAL ASPERGILLUS FUMIGATUS ISOLATES—Annual Evaluation and Performance Measurement Report.2 1 20/60 

1.8—N. GONORRHOEAE WHOLE GENOME SEQUENCING (WGS)—Annual Evaluation and Performance Measurement Report.4 1 10/60 

1.9—GONOCOCCAL (GC) ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) IN JURISDICTION—Annual Evaluation and Performance Measurement Report.4 1 20/60 

1.10—WHOLE GENOME SEQUENCING (WGS) OF 

S. PNEUMONAIE—Annual Evaluation and Performance Measurement Report.

2 1 20/60 

1.11—CLOSTRIDIOIDES DIFFICILE (C. DIFFICLE) 

TESTING IN JURISDICTION—Annual Evaluation 

and Performance Measurement Report.

2 1 20/60 

1.12—ANTIFUNGAL RESISTANT TINEA 

DERMATOPHYTES—Annual Evaluation and Performance Measurement Report.

3 1 20/60 

1.13—ANTIMICROBIAL SUSCEPTIBILITY TESTING 

(AST) OF INVASIVE HAEMOPHILUS 

INFLUENZAE (H. INFLUENZAE) IN JURISDICTION—Annual Evaluation and Performance Measurement Report.

2 1 20/60 

1.14—MYCOPLASMA GENTALIUM (MG)—Annual 

Evaluation and Performance Measurement Report.

4 1 20/60 

1.15—MOLECULAR Mtb TESTING—Annual Evaluation and Performance Measurement Report.Up to 20 1 10/60 

1.16—C. AURIS WHOLE GENOME SEQUENCING 

(WGS) IN JURISDICTION—Annual Evaluation and 

Performance Measurement Report.

Up to 57 1 10/60 

1.17—MONITORING CRE CRPA IN COMPANION 

ANIMALS TO FROM HUMANS—Annual Evaluation and Performance Measurement Report.

Up to 2 1 20/60 

1.18—HEALTHCARE WASTEWATER–BASED SURVEILLANCE—Annual Evaluation and Performance 

Measurement Report.

Up to 2 1 20/60 

1.19—COMMUNICATION AND COORDINATION OF 

ACTIONABLE EPI LAB DATA IN JURISDICTION—Annual Evaluation and Performance Measurement Report.

57 1 10/60 

1.20—CHARACTERIZATION OF THE CLINICAL 

LABORATORY NETWORK IN JURISDICTION— 

Annual Evaluation and Performance Measurement 

Report.

57 1 10/60 

1.21 NEISSERIA GONORRHOEAE ETEST FOR 

SHARP.

17 1 20/60 

AR Lab Network Annual Report of Testing Methods 

for Carbapenemase-producing Organisms.

57 1 2 

AR Lab Network Monthly Data Report Form for 

Carbapenemase-producing Organisms.

57 1302 20/60 

AR Lab Network Alert Report Form for 

Carbapenemase-producing Organisms.

57 214 3/60 

AR Lab Network Alert and Monthly Data Report Form 

for Candida.

Up to 57 1671 20/60 

AR Lab Network Form for Phylogenetic Tree-level 

Mycotics Reporting.

Up to 57 30 6/60 

AR Lab Network Alert and Monthly Data Report Form 

for Neisseria gonorrhoeae.

17 93 6/60 

AR Lab Network DAART data elements for Neisseria 

gonorrhoeae.

4 50 10/60 

HL7 Messages updates—IT Maintenance .................. 32 4 20/60 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 193 / Friday, October 4, 2024 / Notices 80903 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of 

respondents Form name Number of respondents 

Average 

number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Implementation of new HL7 messages—IT Initial Set 

up.

11 4 3 

CSV files updates for Carbapenemase-producing organisms—IT Maintenance.24 1 1 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–22958 Filed 10–3–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifiers: CMS–R–65] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information (including each proposed 

extension or reinstatement of an existing 

collection of information) and to allow 

60 days for public comment on the 

proposed action. Interested persons are 

invited to send comments regarding our 

burden estimates or any other aspect of 

this collection of information, including 

the necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions, 

the accuracy of the estimated burden, 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected, and the use of automated 

collection techniques or other forms of 

information technology to minimize the 

information collection burden. 

DATES: Comments must be received by 

December 3, 2024. 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number. To be assured 

consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

Submission’’ or ‘‘More Search Options’’ 

to find the information collection 

document(s) that are accepting 

comments. 

2. By regular mail. You may mail 

written comments to the following 

address: 

CMS, Office of Strategic Operations and 

Regulatory Affairs, Division of 

Regulations Development, Attention: 

Document Identifier/OMB Control 

Number: Room C4–26–05, 7500 

Security Boulevard, Baltimore, 

Maryland 21244–1850. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, please access the CMS PRA 

website by copying and pasting the 

following web address into your web 

browser: https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/ 

PaperworkReductionActof1995/PRAListing. 

FOR FURTHER INFORMATION CONTACT: 

William N. Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: 

Contents 

This notice sets out a summary of the 

use and burden associated with the 

following information collections. More 

detailed information can be found in 

each collection’s supporting statement 

and associated materials (see 

ADDRESSES). 

CMS–R–65 Final Peer Review 

Organizations Sanction and Supporting 

Regulations 

Under the PRA (44 U.S.C. 3501– 

3520), federal agencies must obtain 

approval from the Office of Management 

and Budget (OMB) for each collection of 

information they conduct or sponsor. 

The term ‘‘collection of information’’ is 

defined in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA 

requires federal agencies to publish a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, before 

submitting the collection to OMB for 

approval. To comply with this 

requirement, CMS is publishing this 

notice. 

Information Collections 

1. Type of Information Collection 

Request: Extension of a currently 

approved collection; Title of 

Information Collection: Final Peer 

Review Organizations Sanction and 

Supporting Regulations; Use: The Peer 

Review Improvement Act of 1982 

amended Title XI of the Social Security 

Act (the Act), creating the Utilization 

and Quality Control Peer Review 

Organization Program. Section 1156 of 

the Act imposes obligations on health 

care practitioners and others who 

furnish or order services or items under 

Medicare. This section also provides for 

sanction actions, if the Secretary 

determines that the obligations as stated 

by this section are not met. Quality 

Improvement Organizations (QIOs) are 

responsible for identifying violations. 

The QIOs may allow practitioners or 

other entities, opportunities to submit 

relevant information before determining 

that a violation has occurred. The 

information collection requirements 

contained in this information collection 

request are used by the QIOs to collect 

the information necessary to make their 

decision. Form Number: CMS–R–65 

(OMB control number: 0938–0444); 

Frequency: Occasionally; Affected 

Public: Private sector—Business or other 

for-profit and Not-for-profit institutions; 

Number of Respondents: 34; Total 

Annual Responses: 34; Total Annual 

Hours: 8,144. (For policy questions 


khammond on DSKJM1Z7X2PROD with NOTICES